Customized Specimen Collection Kits Provide Convenience, Accuracy and Promotion Ideal for Post-Marketing Studies
Rochester, NY, Sept. 22, 2008 – ACM-Pivotal <http://www.acm-pivotal.com/> , the global central laboratory that continually defines the customer-service standard with its flexible approach, is now offering its unique KitKaddySM and lab collection kits to pharmaceutical, biotech and contract research organizations (CROs) that want to promote their brand at the physician level. The environmentally-friendly diagnostic specimen kits have been designed as easy-to-use space savers that help standardize collection across sites and countries. Companies can provide their logo, colors and additional brand elements to be printed on the kits, which will be housed at investigator sites throughout a clinical trial.
ACM-Pivotal will be showcasing its KitKaddy and collection kits, along with its safety testing expertise, at the 11th Registries and Post Approval Studies Congress <http://www.acm-pivotal.com/Registries_contact.html> in Washington, DC Sept. 23-25. The conference agenda is aimed at post-approval studies for improved safety and risk assessment.
ACM-Pivotal has been shipping KitKaddy and lab collection kits to investigator sites globally since 2003 and has received positive response from both investigators and sponsors. Customer demand and increased post-marketing studies have prompted ACM-Pivotal to offer a white-labeled solution to help increase brand awareness of new drugs available on the market.
“Our KitKaddy and lab collection kits are now multipurpose. Not only are they ideal for large safety studies, they provide an additional avenue for sponsors to reinforce their brands to a key audience,” said Elena Logan, VP, Clinical Trials. “With the continued emphasis on post-marketing safety studies, we are pleased to have a solution that is very well aligned with these commitments.”
The KitKaddy is organized with 24 custom visit and protocol-specific laboratory supply trays with the capacity to support large safety studies. Designed specifically for each clinical trial, all the necessary draw supplies are included. ACM-Pivotal’s collection kits enable clinicians to easily adhere to the specimen collection portion of protocols. Furthermore, the kits are assembled in a facility using 100 percent wind energy and manufactured using paperboard that is 100 percent recyclable and made from a renewable resource. The high-quality kits are produced in an ISO 9002 certified facility.
For more information and photos, please visit http://www.acm-pivotal.com/news_KitKaddy_9_22_08.html
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.